Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays

Neoplasia

Volumn 6, Issue 5, 2004, Pages 623-635

  Jiang, Feng ^a   Yin, Zhengnan ^b   Caraway, Nancy P ^a   Li, Ruiyun ^a   Katz, Ruth L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

cDNA microarray; Comparative genomic hybridization; Genomic copy number changes; Primary non small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA;

ADENOCARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE CLUSTER; GENE DELETION; GENE FREQUENCY; GENE LOSS; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENOME ANALYSIS; GENOMICS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 7044264776     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04142     Document Type: Article

References (60)

1. Mountain CT (1997). Revision in the international system for staging of lung cancer. Chest 111, 1710-1717.
2. Wang X, Christiani DC, Mark EJ, Nelson H, Wiencke JK, Gunn L, Wain JC, and Kelsey KT (1999). Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma. Cancer 85, 1734-1739.
3. Johansson M, Jin Y, Mandahl N, Hambraeus G, Johansson L, Mitelman F, Heim S, Lukeis R, Irving L, Garson M, and Hasthorpe S (1990). Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer 2, 116-124.
4. Virmani AK, Fong KM, Kodagoda D, Mclntire D, Hung J, Tonk V, Minna JD, and Gazdar AF (1998). Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21, 308-319.
5. Yoshino I, Fukuyama S, Kameyama T, Shikada Y, Oda S, Maehara Y, and Sugimachi K (2003). Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. Chest 123, 545-550.
6. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, and Minna JD (2000). Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60, 4894-4906.
7. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, Langreck H, Gellert K, Reichel M, Just K, du Manoir S, Cremer T, Dietel M, and Ried T (1997). Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 12, 2331-2335.
8. Luk C, Tsao MS, Bayani J, Shepherd F, and Squire JA (2001). Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 125, 87-99.
9. Michelland S, Gazzeri S, Brambilla E, and Robert-Nicoud M (1999). Comparison of chromosomal imbalances in neuroendocrine and non-small-cell lung carcinomas. Cancer Genet Cytogenet 114, 22-30.
10. Taguchi T, Cheng GZ, Bell DW, Balsara B, Liu Z, Siegfried JM, and Testa JR (1997). Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplification DNA in a human lung carcinoma cell line. Genes Chromosomes Cancer 20, 208-212.
11. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, and Gray JW (2002). Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62, 3636-3640.
12. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, and Brown PO (1999). Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23, 41-46.
13. Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML, and Kallioniemi A (2001). Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 98, 5711-5716.
14. Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, Crossland S, Stratton MR, Wooster R, Campbell C, and Cooper CS (2003), Genome-wide screening for complete genetic loss in prostate cancer by CGH onto cDNA microarrays. Oncogene 22, 1247-1252.
15. Jiang F, Richter J, Gasser T, Sauter G, Mihatsch MJ, and Moch H (1998). Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 153, 1467-1472.
16. Richter J, Jiang F, Gorog JP, Gasser TC, Moch H, Mihatsch MJ, and Sauter G (1997). Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 15, 2860-2864.
17. Jiang F, Lin F, Price R, Gu J, Medeiros LJ, Zhang HZ, Xie SS, Caraway NP, and Katz RL (2002). Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes. J Mol Diagn 4, 144-149.
18. Chiang DY, Brown PO, and Eisen MB (2001). Visualizing associations between genome sequences and gene expression data using genome-mean expression profiles. Bioinformatics 17, 49-55.
19. Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, Zhang W, Guo M, Curran J, Han S, Sidransky D, Buetow K, Madden SL, and Jen J (2001). Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci USA 26, 15203-15208.
20. Racz A, Brass N, Hofer M, Sybrecht GW, Remberger K, and Meese EU (2000). Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. Int J Oncol 17, 67-73.
21. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Saijo T, Kawasaki N, and Kato H (2003). cDNA microarray analysis of gene expression in pathologic Stage IA nonsmall cell lung carcinomas. Cancer 97, 2798-2805.
22. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, and Knuutila S (2002). Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 22, 5804-5813.
23. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, and Kawakami Y (2000). Intra-cellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89, 334-341.
24. White ES, Strom SR, Wys NL, and Arenberg DA (2001). Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 166, 7549-7555.
25. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, and Sugimachi K (2002). Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res 6, 3755-3760.
26. White ES, Flaherty KR, Carskadon S, Brant A, lannettoni MD, Yee J, Orringer MB, and Arenberg DA (2003). Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9, 853-860.
27. Wang MZ, Howard B, Fitzgerald MC, and Patz EF Jr (2003). Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 63, 1652-1656.
28. Pincheira R, Chen Q, and Zhang JT (2001). Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer 84, 1520-1527.
29. Xu J, Tyan T, Cedrone E, Savaraj N, and Wang N (1996). Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes Chromosomes Cancer 17, 172-178.
30. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, and Rickert P (2002). Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21, 7749-7763.
31. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, and Meyerson M (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98, 13790-13795.
32. Hamada K, Kohno T, Kawanishi M, Ohwada S, and Yokota J (1998). Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer 22, 232-240.
33. Mariatos G, Gorgoulis VG, Zacharatos P, Kotsinas A, Vogiatzi T, Rassidakis G, Foukas P, Liloglou T, Tiniakos D, Angelou N, Manolis M, Veslemes M, Field JK, and Kittas C (2000). Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status. Int J Cancer 89, 133-141.
34. Lamy A, Sesboue R, Bourguignon J, Dautreaux B, Metayer J, Frebourg T, and Thiberville L (2002). Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int J Cancer 100, 189-193.
35. Junker N, Latini S, Petersen LN, and Kristjansen PE (2003). Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep 10, 609-616.
36. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, and Nakamura Y (2003). Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22, 2192-2205.
37. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, and Powell CA (2003). Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 163, 1949-1960.
38. Lerman MI and Minna JD (2000). The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 60, 6116-6133.
39. Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA, and Ji L (2003). CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene 22, 615-626.
40. Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, Sauter G, and Ludwig CU (2002). Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol 8, 521-526.
41. Forbes MA, Cox AM, and Cooper EH (1988). A method to detect the in vitro modification of serum beta-2-microglobulin in health and disease. Clin Chim Acta 177, 89-99.
42. Fan C, Stendahl U, Stjernberg N, and Beckman L (1995). Association between orosomucoid types and cancer. Oncology 6, 498-500.
43. Duche JC, Urien S, Simon N, Malaurie E, Monnet I, and Barre J (2000). Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 33, 197-202.
44. Fukuhara H, Masvuda M, Yageta M, Fukami T, Kuramochi M, Maruyama T, Kitamura T, and Murakami Y (2003). Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg. Oncogene 22, 6160-6165.
45. Eickhoff B, Ruller S, Laue T, Kohler G, Stahl C, Schlaak M, and van der Bosch J (2000). Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. Biol Chem 381, 107-112.
46. Czerwinski M, McLemore TL, Gelboin HV, and Gonzalez FJ (1994). Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 54, 1085-1091.
47. Sagawa N, Fujita H, Banno Y, Nozawa Y, Katoh H, and Kuzumaki N (2003). Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br J Cancer 88, 606-612.
48. Shieh DB, Godleski J, Herndon JE II, Azuma T, Mercer H, Sugarbaker DJ, and Kwiatkowski DJ (1999). Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer 85, 47-57.
49. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y, and Kuzumaki N (1998). Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58, 322-327.
50. Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, and Gazdar AF (1999). Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 91, 1863-1868.
51. Fujii T, Dracheva T, Player A, Chacko S, Clifford R, Strausberg RL, Buetow K, Azumi N, Travis WD, and Jen J (2002). A preliminary transcriptome map of non-small cell lung cancer. Cancer Res 62, 3340-3346.
52. Saitoh H, Shimura S, Fushimi T, Okayama H, and Shirato K (1997). Detection of surfactant protein-A gene transcript in the cells from pleural effusion for the diagnosis of lung adenocarcinoma. Am J Med 103, 400-404.
53. Betz C, Papadopoulos T, Buchwald J, Dammrich J, and Muller-Hermelink HK (1995). Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res 19, 4283-4286.
54. Shijubo N, Tsutahara S, Hirasawa M, Takahashi H, Honda Y, Suzuki A, Kuroki Y, and Akino T (1992). Pulmonary surfactant protein A in pleural effusions. Cancer 63, 2905-2909.
55. Cui Y, Dinman JD, Kinzy TG, and Peltz SW (1998). The Mof2/Sui1 protein is a general monitor of translational accuracy. Mol Cell Biol 18, 1506-1516.
56. Lian Z, Pan J, Liu J, Zhang S, Zhu M, Arbuthnot P, Kew M, and Feitelson MA (1999). The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene 18, 1677-1687.
57. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, and Krek W (2001). Skp2 is oncogenic overexpressed in human cancers. Proc Natl Acad Sci USA 98, 5043-5048.
58. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, and Takata T (2001). High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 62, 7044-7047.
59. Harper JW (2001). Protein destruction: adapting roles for Cks proteins. Curr Biol 5;11 (11), 431-435.
60. Inui N, Kitagawa K, Miwa S, Hattori T, Chida K, Nakamura H, and Kitagawa M (2003). High expression of Cks1 in human non-small cell lung carcinomas. Biochem Biophys Res Commun 303, 978-984.